MRK

$115.43

Market ClosedAs of Mar 16, 8:01 PM UTC

Merck & Co., Inc.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$115.43
Potential Upside
60%
Whystock Fair Value$184.74
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDrug Manufacturers - General

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bri...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$285.39B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
15.86
Beta
Defensive asset. Lower volatility than the S&P 500.
0.26
Div Yield
Strong income play. Yield provides a meaningful total return floor.
295.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
36.88%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.96

Recent News

Zacks
Mar 16, 2026

Can Merck's New Drugs & Pipeline Ease Keytruda LOE Concerns?

MRK bets on new products and a growing pipeline as Keytruda nears 2028 LOE, with $70B potential commercial opportunities projected by mid-2030s.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
24/7 Wall St.
Mar 16, 2026

This Schwab ETF Holds 100 Dividend Stocks, Charges $6 a Year, and Yields More Than Most Savings Accounts

Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) costs $6 a year on a $10,000 investment, holds 100 dividend stocks, and currently yields 3.39%. With the Fed funds rate sitting at 3.75% and most high-yield savings accounts paying in that same neighborhood, the yield gap is narrow. But SCHD adds something a savings account never will: price ... This Schwab ETF Holds 100 Dividend Stocks, Charges $6 a Year, and Yields More Than Most Savings Accounts

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Insider Monkey
Mar 16, 2026

Here’s Why Merck (MRK) Surged in Q4

Artisan Partners, an investment management company, released its fourth-quarter 2025 investor letter for “Artisan Value Fund”. A copy of the letter can be downloaded here. The Fund seeks to invest in undervalued companies with strong financial condition and attractive business economics. US equities ended a record year with robust fourth-quarter gains. AI remains the main […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Mar 16, 2026

Exelixis Highlights Zanzalintinib RCC Trials, Sequencing Debate, and December CRC PDUFA at Leerink

Exelixis (NASDAQ:EXEL) executives and investors spent part of the discussion at a Leerink event focusing on recent renal cell carcinoma (RCC) data, evolving treatment sequencing debates, and the company’s late-stage pipeline plans around its next-generation tyrosine kinase inhibitor (TKI) zanzalinti

BEARISH
Negative press. News cycle fixated on risk factors or misses.
MarketBeat
Mar 16, 2026

Exelixis Highlights $2.4B 2026 Outlook, Cabometyx Momentum and Zanzalintinib Catalysts at Conference

Exelixis (NASDAQ:EXEL) detailed its commercial momentum for cabozantinib and outlined key upcoming clinical catalysts for zanzalintinib during a discussion at the Citizens Life Sciences Conference featuring Andrew Peters. Cabozantinib performance and 2026 outlook Peters said 2025 was “an exciting y

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.